NEW YORK (GenomeWeb News) – Drug development service company Covance today announced an alliance and service agreement with M2Gen to match patients for biomarker-driven oncology trials with the right treatment or clinical trial.

Under the terms of the deal, Covance will be the preferred provider for M2Gen for DNA/RNA sequencing, gene expression analysis, and genotyping analysis services, which will be done at Covance's genomics laboratory in Seattle.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.